Hirotoshi Iihara, Masamichi Iwai, Ryo Morita, Yukiyoshi Fujita, Keiko Ohgino, Takuma Ishihara, Chiemi Hirose, Yasuyuki Suzuki, Ken Masubuchi, Hitoshi Kawazoe, Daisuke Kawae, Kanako Aihara, Satoshi Endo, Koichi Fukunaga, Mizuki Yamazaki, Takuya Tamura, Yu Kitamura, Shin Fukui, Junki Endo, Akio Suzuki
BACKGROUND: Mirtazapine blocks 5-hydroxytryptamine type (5-HT)2A , 5-HT2C , 5-HT3 and histamine H1 receptors, similarly to olanzapine. This study aimed to investigate the efficacy and safety of mirtazapine plus granisetron and dexamethasone for carboplatin (CBDCA)-induced nausea and vomiting in patients with thoracic cancers. METHODS: We conducted a prospective, open-label, single-arm, multicenter, phase II trial in four institutions in Japan. Registered patients were moderately to highly emetogenic chemotherapy-naïve, and were scheduled to receive CBDCA at area under the curve (AUC) ≥ 4 mg/mL per minute...
April 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer